• Recall Alert:  EpiPen® Auto-Injector

    Mylan Provides Update on Meridian Medical Technologies', a Pfizer Company, Expanded Voluntary Worldwide Recall of EpiPen® Auto-Injector

    http://newsroom.mylan.com/2017-03-31-Mylan-Provides-Update-on-Meridian-Medical-Technologies-a-Pfizer-Company-Expanded-Voluntary-Worldwide-Recall-of-EpiPen-R-Auto-Injector

     

    Recall: Alert Ventolin 

    December 22, 2015

    Below is important information regarding a recall of GlaxoSmithKline Ventolin HFA Albuterol Sulfate Inhalers.  If you or your child are a user of this device please contact your healthcare provider for futher directions.

    Please Note the Lot #'s involved in the Recall - you can locate the lot # on your medication on the bottom of the carboard box or on top of the canister 

    GlaxoSmithKline voluntary recall of Ventolin HFA (albuterol sulfate) Inhalation Aerosol, 90mcg per actuation, 200 Metered Inhalations

    Product Description

    Ventolin HFA (albuterol sulfate) Inhalation Aerosol, 90mcg per actuation, 200 Metered Inhalations, Rx Only, For Oral Inhalation Only, Net Wt. 18g, GlaxoSmithKline, Research Triangle Park, NC 27709 NDC 1073-0682-20

    Recall Number

     D-0519-2016

    Classification

    Class II

    Code Info 

    Lot#: 5ZP1708, Exp. 12/2016

    Lot#: 5ZP1951, Exp 02/2017

    Product Distributed Qty

    128,704 Inhalers

    Reason For Recall

    Defective Delivery System: Some canisters may not contain sufficient peopellant to deliver the labeled claim of 200 actuations through the end of shelf life.

     

    See link below:

     https://community.aafa.org/blog/glaxosmithkline-recalls-ventolin-hfa-albuterol-sulfate-inhalers

     

    October 30, 2015

     

    Recall Alert: Auvi-Q

     

    Dear Parents:

     

    Below is important information regarding a recall of Auvi-Q Auto Injectors.   If you or your child are a user of this device, please contact your healthcare provider for further directions regarding the recall.

     

    Sanofi US Issues Voluntary Nationwide Recall of AuviQ® Due to Potential Inaccurate Dosage Delivery

    Sanofi US is voluntarily recalling all Auvi‑Q® (epinephrine injection, USP). The recall involves all Auvi‑Q currently on the market and includes both the 0.15 mg and 0.3 mg strengths for hospitals, retailers and consumers. This includes lot number 2299596 through 3037230, which expire March 2016 through December 2016. The products have been found to potentially have inaccurate dosage delivery.

    If a patient experiencing a serious allergic reaction (i.e., anaphylaxis) did not receive the intended dose, there could be significant health consequences, including death because anaphylaxis is a potentially life‑threatening condition. As of October 26, 2015, Sanofi has received 26 reports of suspected device malfunctions in the US and Canada. None of these device malfunction reports have been confirmed. In these reports, patients have described symptoms of the underlying hypersensitivity reaction. No fatal outcomes have been reported among these cases.

     

    Auvi‑Q (epinephrine injection, USP) is used to treat life‑threatening allergic reactions (anaphylaxis) in people who are at risk for or have a history of these reactions. Auvi‑Q is packaged with two active devices and one trainer device in a corrugate box. Auvi‑Q was distributed throughout the United States via wholesalers, pharmacies and hospitals. All Auvi‑Q is being recalled.

    Sanofi US is notifying its distributors and customers who include doctors, pharmacies, wholesalers and other customers in the supply chain by letter, fax, email and phone calls and is arranging for return and reimbursement of all recalled products.

     

    Customers with questions regarding this recall can go to www.Auvi‑Q.com and call1‑866‑726‑6340 Monday through Friday 8 a.m. to 8 p.m. ET for information about how to return their Auvi‑Q devices. Customers may also email cs@sanofi.com. Sanofi US will provide reimbursement for out of pocket costs incurred for the purchase of new epinephrine auto‑injectors with proof of purchase.

     

    Customers should immediately contact their healthcare provider (HCP) for a prescription for an alternate epinephrine auto‑injector. In the event of a life‑threatening allergic reaction (anaphylaxis), patients should only use their Auvi‑Q device if another epinephrine auto‑injector is not available, and then call 911 or local medical emergency services. Customers should contact their physician or HCP if they have experienced any problems that may be related to taking or using this drug product.

     

    Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

    Complete and submit the report Online: www.fda.gov/medwatch/report.htm or by Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1‑800‑332‑1088 to request a reporting form, then complete and return to the address on the pre‑addressed form, or submit by fax to 1‑800‑FDA‑0178

    This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

    Sanofi US is committed to patient safety and the quality of Auvi‑Q, and will continue to work closely with customers and regulatory authorities to resolve this issue in a timely manner.

     

     

    Ridgefield School District Nurses